Newsroom

Absci 2d ago

Absci will be at the Goldman Sachs 47th Annual Global Healthcare Conference! Join our presentation tomorrow, June 9 to hear the latest updates on our generative AI designed therapeutics programs. We will be sharing the archived webcast on our investor relations website so you don’t miss a beat. View the presentation here: https://lnkd.in/eNq5pz8z 📍 Don’t miss out on the conversation in Miami!

View post on LinkedIn

Absci 5d ago

We were recently featured in a CNBC article describing Absci as leading what could be a “GLP-1 moment for hair loss.” Highlights: “While the AI drug discovery space is crowded conceptually, Absci’s real-world traction, breadth of capabilities, and growing data/partner ecosystem gives it a defensible multi-year lead in the race to AI-designed medicines.” At Absci, we're rapidly advancing our AI-designed anti-PRLR antibody, ABS-201 which has the potential to introduce the first new mechanism of action for androgenetic alopecia in nearly three decades. ➡️ Read the full CNBC piece here: https://lnkd.in/exNVbJdS

View post on LinkedIn

Absci 2w ago

Absci is presenting at the 14th World Congress for Hair Research in Seoul 🇰🇷 Prof. Ralf Paus MD, DSc, FRSB will present: Prolactin Receptor Blockade with ABS-201 Promotes Hair Follicle Growth and Stem Cell Activation in Human Male Scalp Skin. ABS-201, which is currently in human clinical trials, targets the prolactin receptor and has demonstrated hair follicle stimulation in translational human ex vivo scalp models, including positive effects on the stem cell niche and the modulation of select growth-associated factors. We hope to see you at #HairResearch2026! 🗓️ Saturday, May 30 | 10:50 AM KST 🔬 Session: Emerging Treatment for AGA View the session details: https://lnkd.in/dh9KMWzu

View post on LinkedIn